A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly

Journal of Thoracic Oncology

Volumn 1, Issue 2, 2006, Pages 141-145

  Chen, Yuh Min ^a,c   Perng, Reury Perng ^a   Tsai, Chun Ming ^a   Whang Peng, Jacqueline ^b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Carboplatin; Cisplatin; Elderly; Non small cell lung cancer; Paclitaxel

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; GRANISETRON; METOPROPRAMIDE; PACLITAXEL; PLATINUM; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG ERUPTION; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; HYPOTENSION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS PNEUMOTHORAX; STATISTICAL ANALYSIS; SURVIVAL TIME; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; TREATMENT RESPONSE; AGE; CANCER STAGING; DRUG COMBINATION; DRUG CONTRAINDICATION; FOLLOW UP; HOSPITALIZATION; LUNG RESECTION; LUNG TUMOR; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; TAIWAN; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PACLITAXEL; PNEUMONECTOMY; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TAIWAN; TREATMENT OUTCOME;

EID: 34247855822     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01243894-200602000-00007     Document Type: Article

References (31)

1. Schottenfeld D. Etiology and epidemiology of lung cancer. In HI Pass, JB Mitchell, DH Johnson, et al. (Eds.), Lung cancer: Principles and practice. Philadelphia: Lippincott Williams & Wilkins, 2000. Pp. 367-388.
2. Lee-Chiong TL Jr, Matthay RA. Lung cancer in the elderly patient. Clin Chest Med 1993;14:453-478.
3. Kuo CW, Chen YM, Chao JY, Tsai CM, Perng RP. Non-small cell lung cancer in very young and very old patients. Chest 2000;117:354-357.
4. Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. Chemotherapy for non-small-cell lung cancer in elderly patients. Chest 2006;128:132-139.
5. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592: A randomized trial. J Natl Cancer Inst 2002;94:173-181.
6. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998;4:1087-1100.
7. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-3859.
8. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 2004;22:330-353.
9. Yau T, Asley S, Smith I, O'Brien M. Time and chemotherapy treatment trends in the elderly (age>70) with lung cancer in a single UK cancer centre (Abstract). Proc Am Soc Clin Oncol 2004;22:a7128.
10. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000;18:623-631.
11. Greco FA, Hainsworth JD. Paclitaxel-based therapy in non-small-cell lung cancer: Improved third generation chemotherapy. Ann Oncol 1999;10 (Suppl 5):S63-S67.
12. Belani CP, Kearns CM, Zuhowski EG, et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:676-684.
13. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
14. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-1381.
15. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48. Geneva, Switzerland, World Health Organization, 1979.
16. Greco FA, Hainsworth JD. Paclitaxel-based therapy in non-small-cell lung cancer: Improved third-generation chemotherapy. Ann Oncol 1999;10 (Suppl 5):S63-S67.
17. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial. J Clin Oncol 1996;14:2054-2060.
18. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-1870.
19. Kosmidis PA, Mylonakis N, Fountzilas G, et al. Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study. Ann Oncol 1997;8:697-699.
20. Laohavinij S, Maoleekoonpairoj S, Cheirsilpa A, et al. Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer. Lung Cancer 1999;26:175-185.
21. Gandara DR, Ohe Y, Kubota K, et al. Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials (Abstract). Proc Am Soc Clin Oncol 2004;22:a7007.
22. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol. 2002;13:1539-1549.
23. Marsland TA, Garfield DH, Khan MM, et al. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: Results of two phase II, multicenter trials. Lung Cancer 2006;47:111-120.
24. Usui K, Inoue A, Ishimoto O, et al. A phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC) (Abstract). Proc Am Soc Clin Oncol 2006;23:a7248.
25. Koamoto I, Moriyama E, Kishi H, et al. Multicenter phase II study of the combination of carboplatin and paclitaxel as first line treatment in elderly patients with advanced non-small cell lung cancer (NSCLC) (Abstract). Proc Am Soc Clin Oncol 2004;22:a7239.
26. Ramalingam S, Belani CP, Barstis J, et al. Treatment of elderly nonsmall cell lung cancer (NSCLC) patients with three different schedules of weekly paclitaxel in combination with carboplatin: Sub-analysis of a randomized trial (Abstract). Proc Am Soc Clin Oncol 2003;21:a2693.
27. Molinier O, Milleron B, Breton JL, et al. Multicenter phase II trial of carboplatin and weekly paclitaxel as first line treatment in elderly patients with non small cell lung cancer: Preliminary results (Abstact). Proc Am Soc Clin Oncol. 2003;21:a2786.
28. Choi IS, Kim BS, Park SR, et al. Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. Lung Cancer 2003;39:99-101.
29. Chen YM, Perng RP, Shih JF, et al. A randomized phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated. Br J Cancer 2004;90:359-365.
30. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
31. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.